He received extensive postdoctoral training in the Department of Experimental Therapeutics at MD Anderson Cancer Center from 1998-2002. Since becoming an independent investigator in 2007, Dr. Liu has focused on studying the role of erbB3 in breast cancer development. The main research program in Dr. Liu’s laboratory is to understand the biology of receptor tyrosine kinase (RTK) signaling in drug resistance and tumor metastasis, and to identify novel approach overcoming the resistance and enhancing therapeutic efficacy in cancer treatment.